RESUMEN
To discover the new medical entity from edible marine algae, our continuously natural product investigation focused on endophytes from marine macroalgae Grateloupia sp. Two new azaphilones, 8a-epi-hypocrellone A (1), 8a-epi-eupenicilazaphilone C (2), together with five known azaphilones, hypocrellone A (3), eupenicilazaphilone C (4), ((1E,3E)-3,5-dimethylhepta-1,3-dien-1-yl)-2,4-dihydroxy-3-methylbenzaldehyde (5), sclerotiorin (6), and isochromophilone IV (7) were isolated from the alga-derived fungus Penicillium sclerotiorum. The structures of isolated azaphilones (1-7) were elucidated by spectrometric identification, especially HRESIMS, CD, and NMR data analyses. Concerning bioactivity, cytotoxic, anti-inflammatory, and anti-fibrosis activities of those isolates were evaluated. As a result, compound 1 showed selective toxicity toward neuroblastoma cell line SH-SY5Y among seven cancer and one fibroblast cell lines. 20 µM of compounds 1, 3, and 7 inhibited the TNF-α-induced NFκB phosphorylation but did not change the NFκB activity. Compounds 2 and 6 respectively promoted and inhibited SMAD-mediated transcriptional activities stimulated by TGF-ß.
Asunto(s)
Antiinflamatorios/farmacología , Antineoplásicos/farmacología , Benzopiranos/farmacología , Microalgas , Penicillium , Pigmentos Biológicos/farmacología , Animales , Antiinflamatorios/química , Antiinflamatorios/uso terapéutico , Antineoplásicos/química , Antineoplásicos/uso terapéutico , Organismos Acuáticos , Benzopiranos/química , Benzopiranos/uso terapéutico , Línea Celular Tumoral/efectos de los fármacos , Fibroblastos/efectos de los fármacos , Alimentos Funcionales , Neuroblastoma/tratamiento farmacológico , Pigmentos Biológicos/química , Pigmentos Biológicos/uso terapéutico , Relación Estructura-ActividadRESUMEN
Myocardial ischemia/reperfusion injury (MI/RI) is an urgent problem with a great impact on health globally. However, its pathological mechanisms have not been fully elucidated. Hydroxysafflor yellow A (HSYA) has a protective effect against MI/RI. This study is aimed at further clarifying the relationship between HSYA cardioprotection and calcium overload as well as the underlying mechanisms. We verified the protective effect of HSYA on neonatal rat primary cardiomyocytes (NPCMs) and human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) from hypoxia-reoxygenation (HR) injury. To explore the cardioprotective mechanism of HSYA, we employed calcium fluorescence, TUNEL assay, JC-1 staining, and western blotting. Finally, cardio-ECR and patch-clamp experiments were used to explain the regulation of L-type calcium channels (LTCC) in cardioprotection mediated by HSYA. The results showed that HSYA reduced the levels of myocardial enzymes and protected NPCMs from HR injury. HSYA also restored the contractile function of hiPSC-CMs and field potential signal abnormalities caused by HR and exerted a protective effect on cardiac function. Further, we demonstrated that HSYA protects cardiomyocytes from HR injury by decreasing mitochondrial membrane potential and inhibiting apoptosis and calcium overload. Patch-clamp results revealed that MI/RI caused a sharp increase in calcium currents, which was inhibited by pretreatment with HSYA. Furthermore, we found that HSYA restored contraction amplitude, beat rate, and field potential duration of hiPSC-CMs, which were disrupted by the LTCC agonist Bay-K8644. Patch-clamp experiments also showed that HSYA inhibits Bay-K8644-induced calcium current, with an effect similar to that of the LTCC inhibitor nisoldipine. Therefore, our data suggest that HSYA targets LTCC to inhibit calcium overload and apoptosis of cardiomyocytes, thereby exerting a cardioprotective effect and reducing MI/RI injury.
Asunto(s)
Apoptosis/efectos de los fármacos , Calcio/efectos adversos , Chalcona/análogos & derivados , Daño por Reperfusión Miocárdica/tratamiento farmacológico , Pigmentos Biológicos/uso terapéutico , Quinonas/uso terapéutico , Animales , Chalcona/farmacología , Chalcona/uso terapéutico , Humanos , Pigmentos Biológicos/farmacología , Quinonas/farmacología , Ratas , Ratas Sprague-DawleyRESUMEN
Background: Echinochrome A (EchA) is a pigment from sea urchins. EchA is a polyhydroxylated 1,4-naphthoquinone that contains several hydroxyl groups appropriate for free-radical scavenging and preventing redox imbalance. EchA is the most studied molecule of this family and is an active principle approved to be used in humans, usually for cardiopathies and glaucoma. EchA is used as a pharmaceutical drug. Methods: A comprehensive literature and patent search review was undertaken using PubMed, as well as Google Scholar and Espacenet search engines to review these areas. Conclusions: In the bloodstream, EchA can mediate cellular responses, act as a radical scavenger, and activate the glutathione pathway. It decreases ROS imbalance, prevents and limits lipid peroxidation, and enhances mitochondrial functions. Most importantly, EchA contributes to the modulation of the immune system. EchA can regulate the generation of regulatory T cells, inhibit pro-inflammatory IL-1ß and IL-6 cytokine production, while slightly reducing IL-8, TNF-α, INF-α, and NKT, thus correcting immune imbalance. These characteristics suggest that EchA is a candidate drug to alleviate the cytokine storm syndrome (CSS).
Asunto(s)
Síndrome de Liberación de Citoquinas/tratamiento farmacológico , Naftoquinonas/farmacología , Naftoquinonas/uso terapéutico , Pigmentos Biológicos/farmacología , Pigmentos Biológicos/uso terapéutico , Erizos de Mar/química , Animales , Síndrome de Liberación de Citoquinas/metabolismo , Humanos , Inmunidad/efectos de los fármacos , Oxidación-Reducción/efectos de los fármacos , Especies Reactivas de Oxígeno/metabolismoRESUMEN
NEW FINDINGS: What is the central question of this study? What are the potential therapeutic roles of ginsenoside Rb1 and hydroxysafflor yellow A (HSYA) in polycystic ovary syndrome (PCOS). What is the main finding and its importance? HSYA restored the oestrous cycles of PCOS mice, reduced follicular cysts in ovaries and rescued abnormal hormone secretion; ginsenoside Rb1 did not ameliorate the main symptoms of PCOS mice. HSYA alleviated oxidative stress along with an enhancement of antioxidant enzyme activity. This highlights a potential role of HSYA in PCOS therapy. ABSTRACT: Polycystic ovary syndrome (PCOS) is the most common endocrine disease resulting in female infertility. Hydroxysafflor yellow A (HSYA) and ginsenoside Rb1 have been shown to have antioxidant properties, but little is known about their impact in PCOS. Here dehydroepiandrosterone was used to induce PCOS in a mouse model that was characterized by an irregular oestrous cycle, cystic follicles and an elevated serum testosterone level. Supplementation of HSYA restored the oestrous cycle of PCOS mice, reduced follicular cysts in PCOS mouse ovaries and brought about a decline in serum testosterone level, while ginsenoside Rb1 did not ameliorate the above symptoms of PCOS mice. After HSYA treatment, there was elevation of serum oestradiol, progesterone, luteinizing hormone and anti-Müllerian hormone levels and a reduction of follicle-stimulating hormone level, but ginsenoside Rb1 only rescued the levels of follicle-stimulating hormone and anti-Müllerian hormone. Further analysis evidenced that HSYA reversed the expression of steroid hormone secretion-related genes Star, Hsd3b1, Cyp11a1 and Cyp19a1. In PCOS mice HSYA weakened the elevation of ovarian malondialdehyde, which is regarded as a biomarker for oxidative stress. Moreover, HSYA improved reduced glutathione content accompanied by a simultaneous increase in reduced to oxidized glutathione ratio, and enhanced the activities of the antioxidant enzymes superoxide dismutase, glutathione peroxidase and catalase. Collectively, HSYA exerted beneficial effects on PCOS mice by restoring hormone secretion and alleviating oxidative stress.
Asunto(s)
Chalcona/análogos & derivados , Estrés Oxidativo/efectos de los fármacos , Hormonas Peptídicas/sangre , Pigmentos Biológicos/uso terapéutico , Síndrome del Ovario Poliquístico/sangre , Síndrome del Ovario Poliquístico/tratamiento farmacológico , Quinonas/uso terapéutico , Animales , Chalcona/farmacología , Chalcona/uso terapéutico , Femenino , Hormona Folículo Estimulante/sangre , Hormona Luteinizante/sangre , Ratones , Ratones Endogámicos ICR , Estrés Oxidativo/fisiología , Pigmentos Biológicos/farmacología , Progesterona/sangre , Quinonas/farmacología , Resultado del TratamientoRESUMEN
BACKGROUND: Sepsis is an inevitable stage of bacterial invasion characterized by the deregulated inflammatory response, resulting in multiorgan dysfunction syndrome. Acute liver injury is a common and serious complication in patients with severe sepsis. The most of conventional antibiotics in managing sepsis are effective, but they are accompanied by undesirable side effects. Therefore, the ongoing study aimed to evaluate the efficacy of echinochrome (Ech) pigment isolated from sea urchins on sepsis-induced liver damage using cecal ligation and puncture (CLP) model. MATERIALS AND METHODS: Male albino rats were randomly divided into three groups: sham group, CLP-induced sepsis, and septic rats treated with Ech. The estimation of liver function markers and oxidative status were analyzed. RESULTS: The results demonstrated that Ech administration significantly improved liver function, as indicated by the decreased liver enzyme activities such as alanine transaminase, gamma-glutamyl transferase, lactate dehydrogenase, aspartate transaminase, and alkaline phosphatase, as well as the increase of albumin content. Moreover, Ech could counteract the hepatic oxidative stress induced by CLP via a marked increment in glutathione content and antioxidant enzyme activities (superoxide dismutase, catalase, glutathione peroxidase, glutathione reductase and glutathione-s-transferase), as well as downregulation of malondialdehyde, nitric oxide, and hydrogen peroxide formation. In addition, the Ech treatment repaired, to some extent, the abnormal architecture of hepatic tissues induced by polymicrobial infection. CONCLUSIONS: In conclusion, Ech could be used as a potential alternative antiseptic remedy via oxidative damage attenuation.
Asunto(s)
Hepatopatías/prevención & control , Naftoquinonas/uso terapéutico , Paracentrotus/química , Pigmentos Biológicos/uso terapéutico , Sustancias Protectoras/uso terapéutico , Quinonas/uso terapéutico , Sepsis/complicaciones , Animales , Hepatopatías/diagnóstico , Hepatopatías/etiología , Hepatopatías/metabolismo , Pruebas de Función Hepática , Masculino , Naftoquinonas/farmacología , Estrés Oxidativo/efectos de los fármacos , Pigmentos Biológicos/farmacología , Sustancias Protectoras/farmacología , Quinonas/farmacología , Distribución Aleatoria , Ratas , Ratas Wistar , Sepsis/metabolismo , Resultado del TratamientoRESUMEN
The antitumor effect of hydroxysafflor yellow A (HSYA), an active ingredient of the herb Carthamus tinctorius L. (Asteraceae) (safflower), was investigated in the current work. Researches of HSYA on vasculogenesis inhibition, along with the related molecular mechanisms, including the expression of MMP-2, MMP-9, and p38MAPK (COX-2, ATF-2, p-p38MAPK, and p38MAPK) signaling pathway in H22 tumor-bearing mice or HepG2 cells were performed. The animal experiments proved the level of MMP-2 and MMP-9 in H22-transplanted tumor tissue in mice markedly decreased by HSYA, and results both in vivo and in vitro confirmed that COX-2 expression was reduced significantly via p38MAPK|ATF-2 signaling pathway. According to the outcomes, HSYA suppressed p38MAPK phosphorylation in a concentration-dependent manner, while exerting no effect on the total p38MAPK protein expression. It was also showed that suppression of p38 activation by SB203580 decreased the HepG2 cell viability, proliferation, and migration, wherein HSYA exhibited a similar effect. Furthermore, Western blot analysis on caspase-3 and cleaved-caspase-3 revealed that HSYA could induce apoptosis of HepG2 cells. These findings provided experimental evidences that HSYA might be a promising anticancer agent for HCC.
Asunto(s)
Carcinoma Hepatocelular/enzimología , Chalcona/análogos & derivados , Neoplasias Hepáticas/enzimología , Neovascularización Patológica/enzimología , Quinonas/uso terapéutico , Proteínas Quinasas p38 Activadas por Mitógenos/antagonistas & inhibidores , Proteínas Quinasas p38 Activadas por Mitógenos/metabolismo , Animales , Carcinoma Hepatocelular/tratamiento farmacológico , Carcinoma Hepatocelular/patología , Chalcona/farmacología , Chalcona/uso terapéutico , Relación Dosis-Respuesta a Droga , Inhibidores Enzimáticos/farmacología , Inhibidores Enzimáticos/uso terapéutico , Células Hep G2 , Humanos , Neoplasias Hepáticas/tratamiento farmacológico , Neoplasias Hepáticas/patología , Masculino , Ratones , Neovascularización Patológica/tratamiento farmacológico , Neovascularización Patológica/patología , Fosforilación/efectos de los fármacos , Fosforilación/fisiología , Pigmentos Biológicos/farmacología , Pigmentos Biológicos/uso terapéutico , Quinonas/farmacologíaRESUMEN
Filamentous ascomycetes (Neurospora and Monascus) have been studied for a long time because of their production of secondary metabolites such as microbial pigments. The ascomycetes represent an interesting group of compounds with high potential for medicinal applications. Many recent studies have shown their efficacy in the treatment of serious pathological states such as oncological diseases, neurodegenerative diseases and hyperlipidaemia. Nevertheless, the clinical usability of ascomycetes is still limited. However, this problem can be solved by the use of these compounds with combinations of other therapeutic agents. This strategy can suppress their side effects and improve their therapeutic efficacy. Moreover, their co-application can significantly enhance conventional therapies that are used. This review summarizes and discusses the general principles of this approach, introduced and supported by numerous examples. In addition, the prediction of the future potential application of this methodology is included.
Asunto(s)
Ascomicetos/química , Ascomicetos/metabolismo , Pigmentos Biológicos/metabolismo , Pigmentos Biológicos/uso terapéutico , Animales , Quimioterapia Combinada , HumanosRESUMEN
Advancement in research on dyes obtained from natural sources e.g., plants, animals, insects and micro-organisms is widening the application of natural dyes in various fields. The natural dyes substituted their synthetic analogs at the beginning of twentieth century due to their improved quality, value, ease of production, ease of dyeing and some other factors. This era of dominance ended soon when toxic effects of synthetic dyes were reported. In the last few decades, pigments from micro-organisms especially soil derived bacteria is replacing dyes from other natural sources because of the increasing demand for safe, non-toxic, and biodegradable natural product. Apart from application in agriculture practices, cosmetics, textile, food and paper industries, bacterial pigments have additional biological activities e.g., anti-tumor, anti-fungal, anti-bacterial, immunosuppressive anti-viral, and many more which make them a potential candidate for pharmaceutical industry. Optimization of culture conditions and fermentation medium is the key strategies for large scale production of these natural dyes. An effort has been done to give an overview of pigments obtained from bacteria of soil origin, their dominance over dyes from other sources (natural and synthetic) and applications in the medical world in the underlying study.
Asunto(s)
Antiinfecciosos/aislamiento & purificación , Antineoplásicos/aislamiento & purificación , Bacterias/química , Inmunosupresores/aislamiento & purificación , Pigmentos Biológicos/aislamiento & purificación , Microbiología del Suelo , Antiinfecciosos/farmacología , Antiinfecciosos/uso terapéutico , Antineoplásicos/farmacología , Antineoplásicos/uso terapéutico , Biotecnología/métodos , Inmunosupresores/farmacología , Inmunosupresores/uso terapéutico , Pigmentos Biológicos/farmacología , Pigmentos Biológicos/uso terapéutico , Tecnología Farmacéutica/métodosRESUMEN
BACKGROUND: Hydroxysafflor yellow A (HSYA) is a major active component of yellow pigment extracted from safflowers; this compound possesses potent neuroprotective effects both in vitro and in vivo. However, underlying mechanism of HSYA is not fully elucidated. The present study investigated the protective effects of HSYA in rat spinal cord compression injury model and related mechanisms involved. METHODS: Sprague-Dawley rats were divided as Sham, Control, and HSYA groups (n = 30 per group). Spinal cord injury (SCI) model was induced by application of vascular clips (force of 50 g, 1 min) to the dura at T9-T10 level of vertebra. Injured animals were administered with either HSYA (8 mg/kg at 1 and 6 h after injury, then 14 mg/kg, for a total of 7 days at 24-h time intervals) or equal volume of saline by intraperitoneal injection. RESULTS: From this experiment, we discovered that SCI in rats resulted in severe trauma, which is characterized by tissue damage, lipid peroxidation, neutrophil infiltration, inflammation mediator release, and neuronal apoptosis. However, HSYA treatment significantly reduced the following: (1) degree of tissue injury (histological score) and edema; (2) neutrophil infiltration (myeloperoxidase activity); (3) oxidative stress (superoxide dismutase, malondialdehyde, and nitric oxide); (4) pro-inflammatory cytokine expression (tumor necrosis factor-α, interleukin-6, inducible nitric oxide synthase, cyclooxygenase-2); (5) nuclear factor-κB activation; (6) apoptosis (terminal deoxynucleotidyl transferase dUTP nick end labeling staining and cysteine-aspartic protease-3 activity). Moreover, in a separate set of experiments, we clearly demonstrated that HSYA treatment significantly ameliorated recovery of limb function (as evaluated by Basso, Beattie, and Bresnahan behavioral recovery scores). CONCLUSIONS: Treatment with HSYA restrains development of oxidative stress, inflammation response, and apoptotic events associated with SCI of rats, demonstrating that HSYA is a potential neuroprotectant for human SCI therapy.
Asunto(s)
Apoptosis/fisiología , Chalcona/análogos & derivados , Mediadores de Inflamación/metabolismo , Neuronas/metabolismo , Estrés Oxidativo/fisiología , Quinonas/uso terapéutico , Compresión de la Médula Espinal/metabolismo , Animales , Apoptosis/efectos de los fármacos , Muerte Celular/efectos de los fármacos , Muerte Celular/fisiología , Chalcona/farmacología , Chalcona/uso terapéutico , Mediadores de Inflamación/antagonistas & inhibidores , Masculino , Neuronas/efectos de los fármacos , Neuronas/patología , Estrés Oxidativo/efectos de los fármacos , Pigmentos Biológicos/farmacología , Pigmentos Biológicos/uso terapéutico , Quinonas/farmacología , Ratas , Ratas Sprague-Dawley , Compresión de la Médula Espinal/tratamiento farmacológicoRESUMEN
Dopamine D3 receptor (DRD3) is diminished in patients of Parkinson's disease (PD). Brain-derived neurotrophic factor (BDNF) is responsible for regulating expression of the DRD3 in the brain. Our previous study showed that hydroxysafflor yellow A (HSYA) could increase BDNF content in the striatum of PD mice. This experiment aimed to evaluate whether HSYA can improve the motor dysfunction induced by rotenone through regulating the BDNF/TrkB/DRD3 signaling pathway in mice. Male C57/BL6 mice were intraperitoneally treated with HSYA. Thirty minutes later, they were intragastrically administered with rotenone at a dose of 30 mg/kg. Pole, rotarod and open field tests were investigated at 28 d. Then, tyrosine hydroxylase (TH) in substantia nigra was observed by immunohistochemistry. Dopamine content was detected by high-performance liquid chromatography. The expressions of BDNF, phospho-tropomyosin-related kinase B (p-TrkB), tropomyosin-related kinase B (TrkB), phospho-phosphoinositide 3-kinase (p-PI3K), phosphoinositide 3-kinase (PI3K), phospho-protein kinase B (p-AKT), protein kinase B (AKT), and DRD3 were assayed by western blotting. Behavioral tests showed that rotenone-challenged mice displayed motor dysfunction. However, treatment with HSYA improved motor dysfunction induced by rotenone. HSYA treatment increased not only the number of TH-containing dopaminergic neurons in substantia nigra, but also the dopamine content in the striatum in PD mice. Moreover, the expressions of BDNF, p-TrkB/TrkB, DRD3, p-PI3K/PI3K, p-AKT/AKT were significantly increased in rotenone plus HSYA group. Our results indicated that HSYA improved motor dysfunction in rotenone-induced PD model and the pharmacological action of HSYA was related to regulating BDNF/TrkB/DRD3 signaling pathway, at least, in part.
Asunto(s)
Chalcona/análogos & derivados , Trastornos de la Destreza Motora/tratamiento farmacológico , Trastornos Parkinsonianos/inducido químicamente , Trastornos Parkinsonianos/tratamiento farmacológico , Quinonas/uso terapéutico , Rotenona/toxicidad , Animales , Chalcona/farmacología , Chalcona/uso terapéutico , Dopamina/metabolismo , Masculino , Ratones , Ratones Endogámicos C57BL , Trastornos de la Destreza Motora/inducido químicamente , Trastornos de la Destreza Motora/metabolismo , Trastornos Parkinsonianos/metabolismo , Pigmentos Biológicos/farmacología , Pigmentos Biológicos/uso terapéutico , Quinonas/farmacología , Distribución Aleatoria , Prueba de Desempeño de Rotación con Aceleración Constante/métodosRESUMEN
A certain nucleosomal protein-high mobility group box-1 (HMGB1)-has recently been established as a late mediator of sepsis, with a relatively wide therapeutic window for pharmacological intervention. Pelargonidin (PEL) is a well-known red pigment found in plants; it has important biological activities that are potentially beneficial for human health. In the present study, we investigated whether PEL can modulate HMGB1-mediated inflammatory responses in human umbilical vein endothelial cells (HUVECs) and in mice. The anti-inflammatory activities of PEL were determined by measuring permeability, leukocyte adhesion and migration, and activation of pro-inflammatory proteins in HMGB1-activated HUVECs and mice, as well as the beneficial effects of PEL on survival rate in the mouse sepsis model. The data showed that PEL had effectively inhibited lipopolysaccharide (LPS)-induced release of HMGB1 and suppressed HMGB1-mediated septic responses, such as hyperpermeability, adhesion and migration of leukocytes, and expression of cell adhesion molecules. Furthermore, PEL inhibited the HMGB1-mediated production of tumor necrosis factor alpha (TNF-α) and interleukin 6 (IL-6), as well as the activation of nuclear factor-κB (NF-κB) and extracellular signal-regulated kinases 1 and 2 (ERK1/2). Collectively, these results indicate that PEL could be used to treat various severe vascular inflammatory diseases via the inhibition of the HMGB1 signaling pathway.
Asunto(s)
Antocianinas/uso terapéutico , Antiinfecciosos Locales/uso terapéutico , Proteína HMGB1/toxicidad , Pigmentos Biológicos/uso terapéutico , Sepsis/tratamiento farmacológico , Animales , Antocianinas/química , Antocianinas/farmacología , Antiinfecciosos Locales/química , Antiinfecciosos Locales/farmacología , Supervivencia Celular/efectos de los fármacos , Supervivencia Celular/fisiología , Relación Dosis-Respuesta a Droga , Células Endoteliales de la Vena Umbilical Humana/efectos de los fármacos , Células Endoteliales de la Vena Umbilical Humana/metabolismo , Humanos , Masculino , Ratones , Ratones Endogámicos C57BL , Pigmentos Biológicos/química , Pigmentos Biológicos/farmacología , Sepsis/metabolismo , Resultado del TratamientoRESUMEN
For the first time, we discovered a small proportion of aqueous fraction from Saw Palmetto apart from the fatty acid-rich fraction exhibited pharmacological activity. Therefore, this study aims to explore the anti-tumor potential of red pigmented aqueous fraction of Saw Palmetto, NYG on human hepatocellular carcinoma and its possible targets. Subcutaneous xenograft and orthotopic implantation models of HCC were used to evaluate the tumor inhibitory effect of NYG. Human hepatocellular carcinoma (HCC) cell lines and human umbilical vein endothelial cells (HUVEC) were used as in vitro model. The mRNA expression was conducted by qPCR. Protein expression was monitored by immunoblotting and immunohistochemistry. Cell migration and blood vessel formation were determined by chamber assay and tube formation assay, respectively. Significant tumor inhibition of NYG in dose-dependent manner was observed on subcutaneous xenograft and orthotopic HCC model. NYG has no direct action on cell viability or VEGF secretion of HCC cells. However, NYG reduced in vitro migration and vessel formation activities of HUVEC cells, as well as in vivo intratumoral neovascularization. NYG attenuated extracellular signal-regulated kinases (ERK) activation in endothelial cells, which may be associated with the suppression of migration and tube formation of HUVEC. NYG suppressed tumor expansion of HCC via inhibiting neovascularization, and may be potential adjuvant treatment for HCC.
Asunto(s)
Carcinoma Hepatocelular/tratamiento farmacológico , Neoplasias Hepáticas/tratamiento farmacológico , Pigmentos Biológicos/uso terapéutico , Extractos Vegetales/uso terapéutico , Animales , Carcinoma Hepatocelular/patología , Movimiento Celular/efectos de los fármacos , Proliferación Celular/efectos de los fármacos , Quimioterapia Adyuvante , Activación Enzimática/efectos de los fármacos , Quinasas MAP Reguladas por Señal Extracelular/metabolismo , Células Hep G2 , Células Endoteliales de la Vena Umbilical Humana , Humanos , Neoplasias Hepáticas/patología , Ratones , Modelos Biológicos , Neovascularización Patológica/tratamiento farmacológico , Pigmentos Biológicos/farmacología , Extractos Vegetales/farmacología , Serenoa , Ensayos Antitumor por Modelo de XenoinjertoRESUMEN
Gardenia yellow pigment (GYP) is a collection of compounds with shared structure of crocin, which confers antidepressant activity. GYP is remarkably enriched in Gardenia jasminoides Ellis, implicated in rapid antidepressant effects that are exerted through enhanced neuroplasticity. This study aims to investigate the rapid antidepressant-like activity of GYP and its underlying mechanism. After the optimal dose was determined, antidepressant responses in tail suspension test or forced swim test were monitored at 30 min, 1 day, 3 days, and 7 days post a single GYP administration. Rapid antidepressant potential was tested using learned helplessness paradigm. The expression of proteins involved in hippocampal neuroplasticity was determined. The effect of blockade of protein synthesis on GYP's antidepressant response was examined. Antidepressant response was detected at 30 min, and lasted for at least 3 days post a single administration of GYP. A single administration of GYP also reversed the deficits in learned helplessness test. Thirty minutes post GYP administration, ERK signaling was activated, and its downstream effector phosphorylated eukaryotic elongation factor 2 was inhibited, contributing to increased protein translation. Expression of synaptic proteins GluR1 and synapsin 1 was upregulated. Blockade of protein synthesis with anisomycin blunted the immediate antidepressant response of GYP. CREB signaling and BDNF expression were upregulated at 24 h, but not at 30 min. In conclusion, GYP-induced immediate antidepressant response was dependent on synthesis of proteins, including synaptic proteins. This was followed by enhanced expression of CREB and BDNF, which likely mediated the persistent antidepressant responses.
Asunto(s)
Factor Neurotrófico Derivado del Encéfalo/metabolismo , Depresión/tratamiento farmacológico , Gardenia/química , Regulación de la Expresión Génica/efectos de los fármacos , Hipocampo/efectos de los fármacos , Pigmentos Biológicos/uso terapéutico , Extractos Vegetales/química , Análisis de Varianza , Animales , Proteína de Unión a CREB/metabolismo , Depresión/patología , Modelos Animales de Enfermedad , Conducta Exploratoria/efectos de los fármacos , Desamparo Adquirido , Suspensión Trasera/métodos , Ratones , Pigmentos Biológicos/química , Transducción de Señal/efectos de los fármacos , Transducción de Señal/fisiología , Natación/psicologíaRESUMEN
Violacein-producing bacteria, with their striking purple hues, have undoubtedly piqued the curiosity of scientists since their first discovery. The bisindole violacein is formed by the condensation of two tryptophan molecules through the action of five proteins. The genes required for its production, vioABCDE, and the regulatory mechanisms employed have been studied within a small number of violacein-producing strains. As a compound, violacein is known to have diverse biological activities, including being an anticancer agent and being an antibiotic against Staphylococcus aureus and other Gram-positive pathogens. Identifying the biological roles of this pigmented molecule is of particular interest, and understanding violacein's function and mechanism of action has relevance to those unmasking any of its commercial or therapeutic benefits. Unfortunately, the production of violacein and its related derivatives is not easy and so various groups are also seeking to improve the fermentative yields of violacein through genetic engineering and synthetic biology. This review discusses the recent trends in the research and production of violacein by both natural and genetically modified bacterial strains.
Asunto(s)
Antibacterianos/biosíntesis , Ingeniería Genética , Indoles/química , Pigmentos Biológicos/biosíntesis , Antibacterianos/química , Antibacterianos/uso terapéutico , Chromobacterium/genética , Chromobacterium/metabolismo , Fermentación , Humanos , Indoles/uso terapéutico , Pigmentos Biológicos/química , Pigmentos Biológicos/uso terapéutico , Staphylococcus aureus/efectos de los fármacos , Triptófano/químicaRESUMEN
Edible fungi of the Monascus species have been used as traditional Chinese medicine in eastern Asia for several centuries. Monascus-fermented products possess a number of functional secondary metabolites, including anti-inflammatory pigments (such as monascin and ankaflavin [AK]), monacolins, and dimerumic acid. These secondary metabolites have anti-inflammatory, anti-oxidative, and anti-tumor activities. We found that AK positively regulates several transcription factors associated with the prevention of metabolic syndrome and other diseases, including peroxisome proliferator-activated receptor (PPAR)-gamma, PPAR-alpha, and nuclear factor (erythroid-derived 2)-like 2 (Nrf2). AK reduced hyperglycemia and enhanced pancreatic function via PPAR-gamma activation and increased lipid metabolism due to PPAR-alpha activation. The compound also exerted antioxidant effects via activation of Nrf2. These results suggest that AK belongs to the class of selective peroxisome proliferator-activated receptor modulators (SPPARMs), which are associated with a good safety profile when used in patients suffering from metabolic syndrome. Together with our studies to determine how AK production can be increased during Monascus fermentation, these data demonstrate the great potential of AK as a nutraceutical or therapeutic agent.
Asunto(s)
Flavinas/aislamiento & purificación , Flavinas/uso terapéutico , Síndrome Metabólico/tratamiento farmacológico , Monascus/química , PPAR alfa/agonistas , Animales , Modelos Animales de Enfermedad , Pigmentos Biológicos/aislamiento & purificación , Pigmentos Biológicos/uso terapéutico , Resultado del TratamientoRESUMEN
Galactosemia is an inherited metabolic disease in which galactose is not properly metabolised. There are various theories to explain the molecular pathology, and recent experimental evidence strongly suggests that oxidative stress plays a key role. High galactose diets are damaging to experimental animals and oxidative stress also plays a role in this toxicity which can be alleviated by purple sweet potato colour (PSPC). This plant extract is rich in acetylated anthocyanins which have been shown to quench free radical production. The objective of this Commentary is to advance the hypothesis that PSPC, or compounds therefrom, may be a viable basis for a novel therapy for galactosemia.
Asunto(s)
Antocianinas/uso terapéutico , Suplementos Dietéticos , Galactosemias/dietoterapia , Ipomoea batatas/química , Pigmentos Biológicos/uso terapéutico , Extractos Vegetales/uso terapéutico , Tubérculos de la Planta/química , Acetilación , Animales , Antocianinas/metabolismo , Antioxidantes/metabolismo , Antioxidantes/uso terapéutico , Suplementos Dietéticos/análisis , Galactosemias/metabolismo , Humanos , Ipomoea batatas/metabolismo , Estrés Oxidativo , Fitoterapia , Pigmentos Biológicos/metabolismo , Extractos Vegetales/química , Tubérculos de la Planta/metabolismoRESUMEN
Sponges are considered as the chemical factory in marine environment because of its immense production of chemically diverse compounds. Other than the chemical diversity, these compounds possess remarkable bioactivities. This great potential has aroused applications of sponge-derived compounds as therapeutics and at present, a number of promising compounds are in clinical and preclinical trials. Recently, nutraceuticals have received considerable interest among the health conscious community because of its multiple therapeutic effects. Natural health-promoting substances gain continuous popularity as nutraceuticals due to its reduced risk of side effects. This overview discusses the potentials of marine sponge-derived bioactivities as natural health-promoting compounds.
Asunto(s)
Organismos Acuáticos/metabolismo , Suplementos Dietéticos , Promoción de la Salud , Poríferos/metabolismo , Poríferos/microbiología , Simbiosis , Actinobacteria/crecimiento & desarrollo , Actinobacteria/metabolismo , Animales , Antiinflamatorios no Esteroideos/metabolismo , Antiinflamatorios no Esteroideos/uso terapéutico , Anticolesterolemiantes/metabolismo , Anticolesterolemiantes/uso terapéutico , Antioxidantes/metabolismo , Antioxidantes/uso terapéutico , Organismos Acuáticos/crecimiento & desarrollo , Colágeno/metabolismo , Colágeno/uso terapéutico , Cianobacterias/crecimiento & desarrollo , Cianobacterias/metabolismo , Suplementos Dietéticos/análisis , Hongos/crecimiento & desarrollo , Hongos/metabolismo , Humanos , Pigmentos Biológicos/química , Pigmentos Biológicos/aislamiento & purificación , Pigmentos Biológicos/metabolismo , Pigmentos Biológicos/uso terapéutico , Poríferos/crecimiento & desarrolloRESUMEN
The effect of the yeast red pigment, the result of polymerization of AIR, and of its low molecular weight derivative (presumably devoid of phosphoribosyl moiety) on the formation of amyloid fibrils in vitro was studied. Both the red pigment and its derivative, the result of acid hydrolysis of the original pigment, were shown to diminish the intensity of amyloid bound Thioflavine T fluorescence. Correlation between the decrease of the intensity of Thioflavine T fluorescence and the concentration of both forms of the red pigment was demonstrated. Both forms were also able to compete with Thioflavine T for amyloid fibrils. Electron microscopy permitted to visualize a drop of fibril size in the case of red pigments presence during their formation.
Asunto(s)
Amiloide/química , Materiales Biomiméticos/química , Insulina/química , Pigmentos Biológicos , Enfermedades por Prión/tratamiento farmacológico , Saccharomyces cerevisiae/química , Tiazoles/metabolismo , Amiloide/antagonistas & inhibidores , Amiloide/metabolismo , Amiloide/ultraestructura , Animales , Benzotiazoles , Materiales Biomiméticos/metabolismo , Fluorescencia , Colorantes Fluorescentes/análisis , Colorantes Fluorescentes/metabolismo , Humanos , Concentración de Iones de Hidrógeno , Hidrólisis , Insulina/metabolismo , Microscopía Electrónica , Microscopía Electrónica de Transmisión , Pigmentos Biológicos/química , Pigmentos Biológicos/metabolismo , Pigmentos Biológicos/uso terapéutico , Enfermedades por Prión/metabolismo , Enfermedades por Prión/patología , Soluciones/química , Soluciones/metabolismo , Espectrometría de Masa por Láser de Matriz Asistida de Ionización Desorción , Tiazoles/análisisRESUMEN
Theabrownin (TB), one of the main bioactive components in pu-erh tea, has a significant blood lipid-lowering effect in hyperlipidemic rats. Therefore, it was hypothesized that TB would regulate the activity of key enzymes involved in lipid metabolism and accelerate the catabolism of exogenous cholesterol in rats fed a high fat diet. A total of 90 Sprague-Dawley rats were randomly divided into a normal control group (Group I), a high fat diet group (Group II), and high-fat diet plus TB group (Group III). A total of 10 rats were selected from each group and killed at 15, 30, or 45 d after starting the study for analysis. After feeding 45 d, the contents of TC, TG, and LDL-C levels in Group II were increased by 54.9%, 93.1%, and 134.3% compared with those in Group III, respectively, and the content of HDL-C in Group II was decreased by 55.7%. These effects were inhibited in the rats in Group III, which exhibited no significant differences in these levels compared with Group I, indicating that TB can prevent hyperlipidemia in rats fed a high fat diet. TB enhanced the activity of hepatic lipase and hormone-sensitive triglyceride lipase (HSL) and increased the HSL mRNA expression in liver tissue and epididymis tissue. The HL activity in serum of Group III was increased by 147.6% compared with that in Group II. The content of cholesterol and bile acid in the feces of rats was increased by 21.11- and 4.08-fold by TB. It suggested that TB could promote the transformation and excretion of dietary cholesterol of rats in vivo.
Asunto(s)
Hiperlipidemias/prevención & control , Hipolipemiantes/farmacología , Metabolismo de los Lípidos/efectos de los fármacos , Pigmentos Biológicos/farmacología , Extractos Vegetales/farmacología , Té/química , Tejido Adiposo Blanco/efectos de los fármacos , Tejido Adiposo Blanco/enzimología , Animales , Ácidos y Sales Biliares/análisis , Colesterol/análisis , Colesterol/sangre , Colesterol/metabolismo , Heces/química , Regulación Enzimológica de la Expresión Génica/efectos de los fármacos , Hiperlipidemias/sangre , Hiperlipidemias/metabolismo , Hiperlipidemias/patología , Hipolipemiantes/análisis , Hipolipemiantes/uso terapéutico , Absorción Intestinal/efectos de los fármacos , Lipasa/sangre , Lipasa/genética , Lipasa/metabolismo , Lípidos/análisis , Lípidos/sangre , Hígado/efectos de los fármacos , Hígado/enzimología , Hígado/patología , Masculino , Pigmentos Biológicos/análisis , Pigmentos Biológicos/aislamiento & purificación , Pigmentos Biológicos/uso terapéutico , Extractos Vegetales/aislamiento & purificación , Extractos Vegetales/uso terapéutico , Distribución Aleatoria , Ratas , Ratas Sprague-Dawley , Esterol Esterasa/genética , Esterol Esterasa/metabolismoRESUMEN
A series of mold metabolites of Ascomycetes, structurally belonging to the class of azaphilones, were found to inhibit the heat shock protein Hsp90. In particular, bulgarialactone B was tested for its binding to Hsp90 using surface plasmon resonance and limited proteolysis assays and for its effects on Hsp90 client proteins expression in a series of human tumor cell lines. This compound showed high affinity for Hsp90, interacting with the 90-280 region of the N-terminal domain and down-regulated the Hsp90 client proteins Raf-1, survivin, Cdk4, Akt, and EGFR. Bulgarialactone B and other natural azaphilones showed antiproliferative activity in a panel of human tumor cell lines; their conversion into semisynthetic derivatives by reaction with primary amines increased the antiproliferative activity. Preliminary results indicated in vivo activity of bulgarialactone B against an ascitic ovarian carcinoma xenograft, thus supporting the therapeutic potential of this novel series of Hsp90 inhibitors.